Biogen will advance its tau-targeting Alzheimer’s disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.
Andrea Pfeifer ends 23-year reign at AC Immune; Acadia’s top R&D exec announces retirement
AC Immune will be searching for a new CEO for the first time, as the company announced this week that Andrea Pfeifer plans to retire


